Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (S <u>EASI</u> DE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing
Rademikibart Q2W induced rapid improvements in AD lesions and pruritus during the initial 16 weeks, which were maintained/improved further with rademikibart Q2W or Q4W across an additional 36 weeks. Rademikibart Q2W and Q4W were similarly efficacious and well tolerated. These findings are compatible with those from the published international phase II rademikibart trial, CBP-201-WW001.
Authors
- Raúl Collazo (ORCID: https://orcid.org/0000-0002-7077-7443)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Wei Zheng (ORCID: https://orcid.org/0000-0002-0454-4158)
- Jianzhong Zhang
- Jili Yun
- Jiawang Guo
- Wuban Pan
Institutions
- George Washington University (US)
- Peking University (CN)
- Jiangsu T-mab BioPharma (China) (CN)
- Peking University People's Hospital (CN)
- RG Biopharma (United States) (US)
- Connecting Health Innovations (United States) (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1093/bjd/ljaf347
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.01